



# Esophageal Squamous Cell Carcinomas (ESCC's) Global Impact on Esophageal Cancer Cases

Christian Abnet\*

Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland

## DESCRIPTION

Esophageal cancer, a strong competitor in the area of oncology, manifests in various forms, each presenting unique challenges for diagnosis and treatment. One such variant is Esophageal Squamous Cell Carcinoma (ESCC), a subtype that accounts for a significant proportion of esophageal cancer cases worldwide.

Esophageal cancer, including ESCC, ranks as the seventh most common cancer and the sixth leading cause of cancer-related deaths globally. While the incidence of esophageal adenocarcinoma is rising in Western countries, ESCC remains predominant in certain regions of Asia, particularly China, where it constitutes the majority of esophageal cancer cases.

ESCC is intricately linked to specific risk factors, and its occurrence is often associated with lifestyle and environmental influences. Heavy tobacco and alcohol use significantly elevate the risk of ESCC. Diets low in fruits and vegetables but high in nitrosamines and hot beverages are linked to an increased risk. Certain genetic factors may contribute to an individual's susceptibility to ESCC. Exposure to carcinogens like polycyclic aromatic hydrocarbons and asbestos can heighten the risk.

ESCC is known for its insidious onset, often remaining asymptomatic in its early stages. As the disease progresses, symptoms may include difficulty swallowing (dysphagia), unintentional weight loss, chest pain, and recurrent coughing. Unfortunately, these symptoms often become apparent only in advanced stages, complicating early detection.

Endoscopy remains a fundamental in diagnosing ESCC. This procedure allows direct visualization of the esophagus, enabling the identification of suspicious lesions. Biopsies taken during endoscopy provide histological confirmation of the cancer.

Complementary imaging studies, such as Computed Tomography (CT) scans, positron Emission Tomography (PET) scans, and Endoscopic Ultrasound (EUS), help evaluate the extent of tumor involvement and detect potential metastasis.

Emerging research explores the use of molecular and genetic markers to enhance ESCC diagnosis and prognosis. Identifying specific alterations in genes associated with ESCC may prepare for more personalized treatment approaches.

Surgical resection is a primary treatment option for localized ESCC. Depending on the tumor's location and stage, procedures such as esophagectomy may be employed to remove the cancerous tissue.

Neoadjuvant and adjuvant chemotherapy play important roles in ESCC treatment. Preoperative chemotherapy aims to shrink tumors before surgery, while postoperative chemotherapy targets any remaining cancer cells and reduces the risk of recurrence.

Radiation therapy, often used in combination with surgery or chemotherapy, involves the targeted application of high-energy rays to destroy cancer cells or shrink tumors. This modality is particularly useful in cases where surgery is not feasible.

Immunotherapy, a rapidly evolving field in cancer treatment, is showing potential in ESCC. Checkpoint inhibitors, such as pembrolizumab, are being investigated for their ability to enhance the immune system's response against cancer cells.

Targeted therapies, designed to interfere with specific molecules involved in cancer growth, are also under investigation for ESCC. Drugs targeting Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) pathways are among those being explored.

Prognosis in ESCC is often influenced by the stage at diagnosis. Unfortunately, many cases are identified in advanced stages, contributing to the overall poor prognosis associated with this disease. As research advances, there is optimism regarding early detection methods, novel therapeutic approaches, and a deeper understanding of the genetic basis of ESCC.

Esophageal squamous cell carcinoma presents a formidable challenge in the area of cancer, demanding a comprehensive understanding of its epidemiology, risk factors, and diagnostic and treatment modalities. With ongoing research efforts, there is

**Correspondence to:** Christian Abnet, Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland, E-mail: Christian@bnet.pl

**Received:** 26-Dec-2023, Manuscript No. JCM-24-24619; **Editor assigned:** 28-Dec-2023, Pre QC No. JCM-24-24619(PQ); **Reviewed:** 12-Jan-2024, QC No. JCM-24-24619; **Revised:** 18-Jan-2024, Manuscript No. JCM-24-24619(R); **Published:** 25-Jan-2024, DOI: 10.35248/2157-2518.24.15.435

**Citation:** Abnet C (2024) Esophageal Squamous Cell Carcinomas (ESCC's) Global Impact on Esophageal Cancer Cases. J Carcinog Mutagen. 15:435.

**Copyright:** © 2024 Abnet C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

influence for improved early detection strategies, personalized treatment approaches, and ultimately, better outcomes for individuals struggling with this complex and often insidious form of esophageal cancer. As the scientific community continues to

resolve the enigma of ESCC, the prospects for more effective interventions and increased survival rates become increasingly potential.